🇺🇸 FDA
Pipeline program

REGN1500

R1500-CL-1321

Phase 1 small_molecule completed

Quick answer

REGN1500 for Metabolic Disorders is a Phase 1 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Metabolic Disorders
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials